197 related articles for article (PubMed ID: 2081487)
1. Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution?
Dandona P; Jeremy JY
Drugs; 1990; 40 Suppl 5():16-24. PubMed ID: 2081487
[TBL] [Abstract][Full Text] [Related]
2. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function.
Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
Br J Rheumatol; 1990 Apr; 29(2):116-9. PubMed ID: 2108782
[TBL] [Abstract][Full Text] [Related]
3. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
[TBL] [Abstract][Full Text] [Related]
4. Effects of the prodrug nabumetone, and its active metabolite, 6-MNA, on human and rat gastric mucosal prostanoids and platelet function.
Jeremy JY; Mikhailidis DP; Barradas MA; Kirk RM; Dandona P
Drugs; 1990; 40 Suppl 5():53-6. PubMed ID: 2081494
[No Abstract] [Full Text] [Related]
5. The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism.
Melarange R; Spangler R; Hoult JR
Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):195-200. PubMed ID: 8931119
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): comparison with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Agents Actions; 1992; Spec No():C82-3. PubMed ID: 1442340
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function.
Melarange R; Rashbrook LC
J Pharm Pharmacol; 1987 Sep; 39(9):717-20. PubMed ID: 2445949
[TBL] [Abstract][Full Text] [Related]
8. Nabumetone (BRL 14777, 4-[6-methoxy-2-naphthyl]-butan-2-one): a new anti-inflammatory agent.
Boyle EA; Freeman PC; Mangan FR; Thomson MJ
J Pharm Pharmacol; 1982 Sep; 34(9):562-9. PubMed ID: 6127380
[TBL] [Abstract][Full Text] [Related]
9. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative studies with indomethacin.
Melarange R; Gentry C; O'Connell C; Blower PR; Neil C; Kelvin AS; Toseland CD
Dig Dis Sci; 1992 Dec; 37(12):1847-52. PubMed ID: 1473433
[TBL] [Abstract][Full Text] [Related]
10. Low direct cytotoxicity of nabumetone on gastric mucosal cells.
Arai Y; Tanaka K; Ushijima H; Tomisato W; Tsutsumi S; Aburaya M; Hoshino T; Yokomizo K; Suzuki K; Katsu T; Tsuchiya T; Mizushima T
Dig Dis Sci; 2005 Sep; 50(9):1641-6. PubMed ID: 16133963
[TBL] [Abstract][Full Text] [Related]
11. Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.
Hedner T; Samulesson O; Währborg P; Wadenvik H; Ung KA; Ekbom A
Drugs; 2004; 64(20):2315-43; discussion 2344-5. PubMed ID: 15456329
[TBL] [Abstract][Full Text] [Related]
12. Non-steroidal anti-inflammatory drug, nabumetone, prevents indometacin-induced gastric damage via inhibition of neutrophil functions.
Ishiwata Y; Okamoto M; Yokochi S; Hashimoto H; Nakamura T; Miyachi A; Naito Y; Yoshikawa T
J Pharm Pharmacol; 2003 Feb; 55(2):229-37. PubMed ID: 12635655
[TBL] [Abstract][Full Text] [Related]
13. Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.
Friedel HA; Langtry HD; Buckley MM
Drugs; 1993 Jan; 45(1):131-56. PubMed ID: 7680981
[TBL] [Abstract][Full Text] [Related]
14. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
Nobilis M; Mikušek J; Szotáková B; Jirásko R; Holčapek M; Chamseddin C; Jira T; Kučera R; Kuneš J; Pour M
J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
[TBL] [Abstract][Full Text] [Related]
15. Effects of nabumetone, a new non-steroidal anti-inflammatory drug, on urinary prostaglandin excretion in man.
Giannessi D; Lazzerini G; Filipponi P; Mannarelli C; Vaiani G; Grossi E; De Caterina R
Pharmacol Res; 1993; 28(3):229-41. PubMed ID: 8108313
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers.
Freed MI; Audet PR; Zariffa N; Krishna GG; Ilson BE; Everitt DE; Brown LE; Rizzo SM; Nichols AI; Jorkasky DK
J Clin Pharmacol; 1994 Nov; 34(11):1098-108. PubMed ID: 7876402
[TBL] [Abstract][Full Text] [Related]
17. The unique pharmacologic profile of nabumetone.
Blower PR
J Rheumatol Suppl; 1992 Nov; 36():13-9. PubMed ID: 1474529
[TBL] [Abstract][Full Text] [Related]
18. Nabumetone: a "nonacidic" nonsteroidal antiinflammatory drug.
Dahl SL
Ann Pharmacother; 1993 Apr; 27(4):456-63. PubMed ID: 8477124
[TBL] [Abstract][Full Text] [Related]
19. Fenflumizole: interactions with the arachidonic acid cascade.
Corell T; Hasselmann G; Splawinski J; Wojtaszek B
Acta Pharmacol Toxicol (Copenh); 1983 Oct; 53(4):297-303. PubMed ID: 6417973
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
Melarange R; Gentry C; Durie M; O'Connell C; Blower PR
Dig Dis Sci; 1994 Mar; 39(3):601-8. PubMed ID: 8131699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
